Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Saved in:
| Title: | Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. |
|---|---|
| Authors: | van der Straten L; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands., Stege CAM; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam-Treatment and Quality of Life, Amsterdam, The Netherlands., Kersting S; Department of Hematology, HAGA Teaching Hospital, The Hague, The Netherlands., Nasserinejad K; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dubois J; Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands., Dobber JA; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands., Mellink CHM; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, The Netherlands., van der Kevie-Kersemaekers AF; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, The Netherlands., Evers LM; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands., de Boer F; Department of Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands., Koene HR; Department of Hematology, Antonius Hospital, Nieuwegein, The Netherlands., Schreurs J; Department of Internal Medicine, Martini Hospital, Groningen, The Netherlands., van der Klift M; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., Velders GA; Department of Internal Medicine, Gelderland Valley Hospital, Ede, The Netherlands., van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands., van der Straaten HM; Department of Internal Medicine, St Jansdal Hospital, Harderwijk, The Netherlands., Hoogendoorn M; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands., van Gelder M; Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands., Posthuma EFM; Department of Internal Medicine, Reinier The Graaf Hospital, Delft, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Visser HPJ; Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands., Houtenbos I; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands., Idink CAM; Department of Internal Medicine, ZorgSaam Hospital, Terneuzen, The Netherlands., Issa DE; Department of Internal Medicine, Jeroen Bosch Hospital, s-Hertogenbosch, The Netherlands., Dompeling EC; Department of Hematology, Isala Hospital, Zwolle, The Netherlands., van Zaanen HCT; Department of Internal Medicine, St Franciscus Hospital, Rotterdam, The Netherlands., Veelken JH; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Levenga H; Department of Internal Medicine, Groene Hart Hospital, Gouda, The Netherlands., Tick LW; Department of Internal Medicine, Maxima Medical Center, Eindhoven, The Netherlands., Terpstra WE; Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands., Tonino SH; Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands., Westerweel PE; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Langerak AW; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands., Kater AP; Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. |
| Source: | Blood [Blood] 2023 Sep 28; Vol. 142 (13), pp. 1131-1142. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
